NTX-470 / Nutcracker Therapeutics - LARVOL DELTA

NTX-470, a novel multispecific T cell engager expressed from mRNA targets PSMA and STEAP1 prostate cancer antigens to generate enhanced functional activity (AACR 2024) - "We identified a small number of molecules that are capable of engaging CD3 T cells but display minimal activity in the absence of STEAP1 or PSMA expressing target cells, including molecules that retain low bystander activity and attenuated PSMA binding yet maintain robust target cell killing. These molecules include NTX-470, which targets both STEAP1 and PSMA on tumor cells with minimal bystander activity."

IO biomarker • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • FOLH1 • STEAP1

Nutcracker Therapeutics’ Research Partner, the University of California, San Francisco, Presents Foundational Prostate Cancer Data at AAI 2024 (Businesswire) - "Nutcracker Therapeutics...detailed data presented by its partners at the University of California, San Francisco (UCSF) on foundational prostate cancer antigen research utilized to inform the development of its mRNA drug candidate, NTX-470. The data were presented...on May 4, during the 2024 Annual Meeting of the American Association of Immunologists (AAI) in Chicago....The research presented at AAI was the result of a longstanding partnership between Nutcracker Therapeutics and UCSF."

Preclinical • Prostate Cancer

Nutcracker Therapeutics Demonstrates Enhanced Functional Activity of Prostate Cancer Candidate NTX-470 at the 2024 AACR Annual Meeting (Businesswire) - "Nutcracker Therapeutics...recently presented two posters at the American Association for Cancer Research (AACR) Annual Meeting in San Diego: one showcasing the latest preclinical data for the company’s mRNA drug candidate for prostate cancer, NTX-470; and the other highlighting data on the immunomodulatory cytokine, LIGHT....Data showed NTX-470 successfully engaged CD3 T cells, while retaining low bystander activity and reduced off-tumor binding. Another set of data detailed the design of LIGHT, an immunomodulatory cytokine that is a component of lead drug candidate NTX-250."

Preclinical • Prostate Cancer

Nutcracker Therapeutics to Present Data on mRNA Drug Candidate and Immunomodulatory Cytokine at AACR 2024 (Businesswire) - "Nutcracker Therapeutics, Inc...announced that two poster presentations highlighting the company’s RNA therapeutics pipeline will be introduced at the 2024 American Association for Cancer Research (AACR) Annual Meeting. The first presentation entails LIGHT, an immunomodulatory cytokine that is one of the components of NTX-250, the company’s lead candidate for cervical intraepithelial neoplasia. The second presentation is on preclinical data for Nutcracker’s mRNA drug candidate for prostate cancer, NTX-470."

Preclinical • Cervical Cancer • Genito-urinary Cancer • Gynecologic Cancers • Oncology • Solid Tumor